Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis - a two-year longitudinal MRI/MRSI study of corpus callosum

Abstract

Backgrounds Atrophy of corpus callosum (CC), a white matter structure linking the two hemispheres, is commonly observed in multiple sclerosis (MS). However, the occurrence and processes leading to this alteration are not yet determined.

Goal and methods To better characterize the onset and progression of CC atrophy from the early stage of MS, we performed a two-year follow-up magnetic resonance imaging/magnetic resonance spectroscopic imaging (MRI/MRSI) exploration of CC in 24 patients with clinically isolated syndrome. These patients were explored using the same protocol at month (M)6, M12 and M24. MRI/MRSI techniques were applied to measure CC volume, and relative concentrations of N-acetylaspartate (NAA), creatine/phosphocreatine (Cr) and choline-containing compounds (Cho). A group of matched controls was also explored.

Results Atrophy of CC, not present at baseline, was observed at M12 and progressed over the second year (M24). At baseline, a decrease in relative NAA level was observed in the anterior and posterior body of CC, with normalization during the follow-up period. In the anterior body, an increase in relative Cho level was observed, with normalization at M6. Normal relative Cr levels were observed at all time points in all sub-regions. The rate of CC atrophy was correlated with the change in the Expanded Disability Status Scale (EDSS) during the follow-up period.

Conclusion These results suggest that CC atrophy appears over a period of one year after the first acute inflammatory episode, and that this atrophy is accompanied, especially in the anterior body of CC, by a normalization of the relative Cho levels, marker of acute inflammation, and NAA levels, marker of neuronal dysfunction and/or loss.

Keywords

atrophy CIS longitudinal study MRSI multiple sclerosis white matter

Get full access to this article

View all access options for this article.

References

Chard DT , Griffin CM , Rashid W , Davies GR , Altmann DR , Kapoor R et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis . Mult Scler 2004; 10: 387-391 .

Losseff NA , Wang L , Lai HM , Yoo DS , Gawne-Cain ML , McDonald WI et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119: 2009-2019 .

Fisher E , Rudick RA , Simon JH , Cutter G , Baier M , Lee JC et al. Eight-year follow-up study of brain atrophy in patients with MS . Neurology 2002; 59: 1412-1420 .

Rudick RA , Fisher E , Lee JC , Simon J , Jacobs L . Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group . Neurology 1999; 53: 1698-1704 .

Tiberio M , Chard DT , Altmann DR , Davies G , Griffin CM , Rashid W et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study . Neurology 2005; 64: 1001-1007 .

Ranjeva JP , Pelletier J , Confort-Gouny S , Ibarrola D , Audoin B , Le Fur Y et al. MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis . Mult Scler 2003; 9: 554-565 .

McDonald WI , Compston A , Edan G , Goodkin D , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis . Ann Neurol 2001; 50: 121-127 .

Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS) . Neurology 1983; 33: 1444-1452 .

von Kienlin M , Ziegler A , Le Fur Y , Rubin C , Decorps M , Remy C . 2D-spatial/2D-spectral spectroscopic imaging of intracerebral gliomas in rat brain . Magn Reson Med 2000; 43: 211-219 .

10.

Matson GB . An integrated program for amplitude modulated RF pulse generation and re-mapping with shaped gradients . Magn Reson Imaging 1994; 12: 1205-1225 .

11.

Tkac I , Starcuk Z , Choi IY , Gruetter R . In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time . Magn Reson Med 1999; 41: 649-656 .

12.

Pelletier J , Suchet L , Witjas T , Habib M , Gutt mann CR , Salamon G et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis . Arch Neurol 2001; 58: 105-111 .

13.

Pelletier J , Habib M , Lyon-Caen O , Salamon G , Poncet M , Khalil R . Functional and magnetic resonance imaging correlates of callosal involvement in multiple sclerosis . Arch Neurol 1993; 50: 1077-1082 .

14.

Vanhamme L , van den Boogaart A , Van Huffel S . Improved method for accurate and efficient quantification of MRS data with use of prior knowledge . J Magn Reson 1997; 129: 35-43 .

15.

Turner B , Lin X , Calmon G , Roberts N , Blumhardt LD . Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years . Mult Scler 2003; 9: 21-27 .

16.

De Stefano N , Matthews PM , Filippi M , Agosta F , De Luca M , Bartolozzi ML et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability . Neurology 2003; 60: 1157-1162 .

17.

Kalkers NF , Ameziane N , Bot JC , Minneboo A , Polman CH , Barkhof F . Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype . Arch Neurol 2002; 59: 1572-1576 .

18.

Ge Y , Grossman RI , Udupa JK , Wei L , Mannon LJ , Polansky M et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis . Radiology 2000; 214: 665-670 .

19.

Paolillo A , Pozzilli C , Gasperini C , Giugni E , Mainero C , Giuliani S et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability . J Neurol Sci 2000; 174: 85-91 .

20.

Paolillo A , Piattella MC , Pantano P , Di Legge S , Caramia F , Russo P et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. A monthly MRI study after triple-dose gadolinium-DTPA . J Neurol 2004; 251: 432-439 .

21.

Traboulsee A , Dehmeshki J , Brex PA , Dalton CM , Chard D , Barker GJ et al. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS . Neurology 2002; 59: 126-128 .

22.

Ge Y , Grossman RI , Udupa JK , Babb JS , Nyul LG , Kolson DL . Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter . Radiology 2001; 220: 606-610 .

23.

Dalton CM , Chard DT , Davies GR , Miszkiel KA , Altmann DR , Fernando K et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes . Brain 2004; 127: 1101-1107 .

24.

Sperling RA , Guttmann CR , Hohol MJ , Warfield SK , Jakab M , Parente M et al. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study . Arch Neurol 2001; 58: 115-121 .

25.

Tourbah A , Stievenart JL , Gout O , Fontaine B , Liblau R , Lubetzki C et al. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis . Neurology 1999; 53: 1091-1097 .

26.

Brex PA , Gomez-Anson B , Parker GJ , Molyneux PD , Miszkiel KA , Barker GJ et al. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis . J Neurol Sci 1999; 166: 16-22 .

27.

Fernando KT , McLean MA , Chard DT , MacManus DG , Dalton CM , Miszkiel KA et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis . Brain 2004; 127: 1361-1369 .

28.

De Stefano N , Narayanan S , Matthews PM , Francis GS , Antel JP , Arnold DL . In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis . Brain 1999; 122: 1933-1939 .

29.

Davie CA , Hawkins CP , Barker GJ , Brennan A , Tofts PS , Miller DH et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions . Brain 1994; 117: 49-58 .

30.

Arnold DL , Matthews PM , Francis GS , O'Connor J , Antel JP . Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques . Ann Neurol 1992; 31: 235-241 .

31.

Narayanan S , De Stefano N , Francis GS , Arnaoutelis R , Caramanos Z , Collins DL et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b . J Neurol 2001; 248: 979-986 .

32.

Miller BL , Chang L , Booth R , Ernst T , Cornford M , Nikas D et al. In vivo 1H MRS choline: correlation with in vitro chemistry/histology . Life Sci 1996; 58: 1929-1935 .

33.

Ross AJ , Sachdev PS . Magnetic resonance spectroscopy in cognitive research . Brain Res Brain Res Rev 2004; 44: 83-102 .

34.

Brenner RE , Munro PM , Williams SC , Bell JD , Barker GJ , Hawkins CP et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio . Magn Reson Med 1993; 29: 737-745 .

35.

Adams CW , Poston RN , Buk SJ . Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis . J Neurol Sci 1989; 92: 291-306 .

36.

Oh J , Henry RG , Genain C , Nelson SJ , Pelletier D . Mechanisms of normal appearing corpus callosum injury related to pericallosal T1 lesions in multiple sclerosis using directional diffusion tensor and 1H MRS imaging . J Neurol Neurosurg Psychiatry 2004; 75: 1281-1286 .

37.

Oh J , Pelletier D , Nelson SJ . Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging . Arch Neurol 2004; 61: 1081-1086 .